vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $18.2M, roughly 1.9× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — 2.2% vs -299.9%, a 302.1% gap on every dollar of revenue. On growth, FrontView REIT, Inc. posted the faster year-over-year revenue change (12.0% vs 11.6%).
FVR vs KPTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.2M | $34.1M |
| Net Profit | $400.0K | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | 24.9% | -52.4% |
| Net Margin | 2.2% | -299.9% |
| Revenue YoY | 12.0% | 11.6% |
| Net Profit YoY | — | -232.0% |
| EPS (diluted) | — | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.2M | — | ||
| Q4 25 | $16.5M | $34.1M | ||
| Q3 25 | $16.8M | $44.0M | ||
| Q2 25 | $17.6M | $37.9M | ||
| Q1 25 | $16.2M | $30.0M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | $14.5M | $38.8M | ||
| Q2 24 | — | $42.8M |
| Q1 26 | $400.0K | — | ||
| Q4 25 | $-4.1M | $-102.2M | ||
| Q3 25 | $4.0M | $-33.1M | ||
| Q2 25 | $-2.9M | $-37.3M | ||
| Q1 25 | $-833.0K | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | $-2.4M | $-32.1M | ||
| Q2 24 | — | $23.8M |
| Q1 26 | 24.9% | — | ||
| Q4 25 | — | -52.4% | ||
| Q3 25 | — | -34.6% | ||
| Q2 25 | — | -64.3% | ||
| Q1 25 | — | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | -24.9% | -299.9% | ||
| Q3 25 | 23.9% | -75.2% | ||
| Q2 25 | -16.5% | -98.2% | ||
| Q1 25 | -5.1% | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | -16.7% | -82.7% | ||
| Q2 24 | — | 55.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.19 | $-7.02 | ||
| Q3 25 | $0.19 | $-3.82 | ||
| Q2 25 | $-0.16 | $-4.32 | ||
| Q1 25 | $-0.06 | $-2.77 | ||
| Q4 24 | — | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | — | $-2.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.3M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $514.2M | $-292.9M |
| Total Assets | $869.8M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $9.3M | — | ||
| Q4 25 | $13.5M | $60.5M | ||
| Q3 25 | $19.6M | $37.7M | ||
| Q2 25 | $8.4M | $38.7M | ||
| Q1 25 | $3.3M | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M |
| Q1 26 | — | — | ||
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $514.2M | — | ||
| Q4 25 | $391.2M | $-292.9M | ||
| Q3 25 | $385.2M | $-269.3M | ||
| Q2 25 | $369.9M | $-238.9M | ||
| Q1 25 | $324.7M | $-205.9M | ||
| Q4 24 | — | $-186.0M | ||
| Q3 24 | $1.0K | $-159.6M | ||
| Q2 24 | — | $-132.1M |
| Q1 26 | $869.8M | — | ||
| Q4 25 | $854.4M | $108.4M | ||
| Q3 25 | $846.8M | $96.2M | ||
| Q2 25 | $856.5M | $104.9M | ||
| Q1 25 | $860.8M | $127.7M | ||
| Q4 24 | — | $164.4M | ||
| Q3 24 | $1.0K | $189.5M | ||
| Q2 24 | — | $214.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-11.8M | ||
| Q3 25 | $8.3M | $-5.9M | ||
| Q2 25 | $9.3M | $-18.7M | ||
| Q1 25 | $8.1M | $-39.0M | ||
| Q4 24 | — | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-38.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVR
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
